Arcus Biosciences
Exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $150m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 394 % | (71 %) | 4 % | 121 % | (51 %) | 32 % | 42 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 14 % | (236 %) | (249 %) | (97 %) | (365 %) | (277 %) | (182 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 14 % | (238 %) | (262 %) | (110 %) | (361 %) | (268 %) | (183 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 67 % | 257 % | 291 % | 174 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Arcus Biosciences is a biopharmaceutical company dedicated to developing innovative combination therapies to combat cancer. The company focuses on designing and advancing medicines that improve the lives of cancer patients. Arcus operates in the oncology market, primarily serving patients, healthcare providers, and research institutions. The business model revolves around conducting clinical trials to test the efficacy and safety of their drug candidates, which are then brought to market upon successful approval. Revenue is generated through partnerships, licensing agreements, and eventual sales of approved therapies. Arcus is committed to relentless research and development, leveraging cutting-edge science to create potential cures for cancer.
Keywords: oncology, biopharmaceutical, combination therapies, cancer research, clinical trials, drug development, innovative medicines, healthcare, biotechnology, immunotherapy.